There is a fair bit about this on the other thread if you wanted...

There is a fair bit about this on the other thread if you wanted particulars. But in short, you are right, this does not impact MYX. The issues - as reported by Bloomberg.com in the below link - started from a change in a manufacturing process in a single plant in China. It was then 'copied' by a number of Indian manufacturers and so far it is linked to Zantac and some blood pressure products sold out of those factories in India and China.

Bloomberg did an extensive investigation into the issue and their summation was a lack of FDA oversight and quality controls, with some complacency thrown in led to the current issues.

I believe political pressure is building with both sides largely in agreement that something needs to be done on this so i think the possibility of a bipartisan approach is very real, and what do i mean by that? In short, an embargo on pharmaceutical products from India and China. But i do not know. I find it hard to read the U.S. political environment nowadays.

As for MYX, they recently opened a $100m state of the art manufacturing facility in Greenville (U.S) and they manufacture their own generics and have even started to manufacture for 3rd parties. Their last report reported double digit growth in their manufacturing (MCS) division and they added they expected 'strong growth' to continue in FY20. Personally, i expect this has and will be accelerating even from that 'strong growth' expectation given everything that is happening within this sector. We should keep in mind what we are talking about, some drugs, to make people better, are reported by bloomberg, have a cancer rate of 1/8000, with 1/3390 becoming 'sick'.

I suspect this situation will lead people in the U.S. to ask 'where do my drugs come from?' in numbers of material importance to MYX, whether or not the legislation is changed or fixed.

Prior to this story i rated MYX at about ~$1-$1.2 based on exceptional growth in their specialty drugs, women's health and MCS (project) division, and i expected the generic volume and price to be largely unchanged. I no longer expect that to be the case. I believe the changing generic-drug environment in the U.S. will directly result in increased prices and volumes for MYX's generic drug division. And given this is still the Lion's share of MYX's business, this changes the metrics for the company considerably.

https://www.bloomberg.com/news/features/2019-09-12/how-carcinogen-tainted-generic-drug-valsartan-got-past-the-fda